+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating the effects of felzartamab in adults who have received kidney transplants and later developed microvascular inflammation MVI, a condition involving injury to small blood vessels in the transplanted kidney that may signal rejection. This condition can lead to serious kidney problems over time and sometimes occurs without the usual antibodies, known as isolated MVI. The study aims to understand how felzartamab influences inflammation in the transplanted kidney and overall kidney health. Participants will be randomly assigned to receive either felzartamab or a placebo through intravenous IV infusions. The study is divided into two parts Part A lasts 24 weeks, during which neither participants nor researchers know who receives felzartamab or placebo Part B lasts an additional 28 weeks where all participants receive felzartamab openly. Kidney biopsies will take place at the start, Week 24, and Week 52 to evaluate changes in inflammation. Participants will be involved for about one year, undergoing regular kidney biopsies, lab tests, and monitoring for adverse events. Researchers will assess inflammation resolution, kidney function, immune activity, and overall health. Safety is closely monitored through biopsies and lab results, with adverse events recorded throughout the trial to ensure thorough evaluation of felzartamabs effects.

Age: 18Years - 74YearsAll GendersPhase 2
51 locations